Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
Immunic Inc ( NASDAQ:IMUX ) strengthened its management team with the addition of experienced executives, enhancing its leadership capabilities. The company achieved a positive outcome in the interim analysis of its phase three ensure program for relapsing multiple sclerosis, indicating progress in clinical trials. Immunic Inc ( NASDAQ:IMUX ) presented compelling data at the EAMS Congress, showcasing the potential of its drug candidate, vlu calcium, in treating multiple sclerosis. The company has a strong cash position, with $59.1 million in cash and cash equivalents, expected to fund operations into the third quarter of 2025. Immunic Inc ( NASDAQ:IMUX ) is actively pursuing partnerships with global and regional pharmaceutical companies, indicating potential for strategic collaborations. Research and development expenses increased to $21.4 million for the quarter, reflecting higher external development costs. The company reported a net loss of approximately $24.4 million
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Immunic, Inc. (NASDAQ: IMUX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Immunic to Participate in Investor and Scientific Conferences in FebruaryPR Newswire
- Immunic, Inc. (NASDAQ: IMUX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Immunic, Inc. (NASDAQ: IMUX) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.MarketBeat
- Immunic Highlights 2024 Accomplishments and Upcoming Milestones [Yahoo! Finance]Yahoo! Finance
IMUX
Earnings
- 11/7/24 - Miss
IMUX
Analyst Actions
- 11/25/24 - HC Wainwright
IMUX
Sec Filings
- 2/14/25 - Form SCHEDULE
- 2/12/25 - Form SCHEDULE
- 1/30/25 - Form SCHEDULE
- IMUX's page on the SEC website